2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 566

A Human Monoclonal Antibody Against Domain I Of β2-Glycoprotein I prevents Clotting and Fetal Loss Induced By Polyclonal Anti-Phospholipid Antibodies In Animal Models
Abstract Number: 1187

A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout
Abstract Number: 419

A Long Term Observation Of Rheumatoid Arthritis Who Developed Methotrexate Related Lymphoproliferative Disorders
Abstract Number: 1241

A Low Serum 25(OH) Vitamin D Level As a Risk Factor For Incidence and Severity Of Vertebral Fracture In Glucocorticoid-Induced Osteoporosis In Japan
Abstract Number: 1802

A Major Clinical Response To Anti-Tumor Necrosis Factor Agents Is Associated With a Reduced Development Of Fatty Changes In The Spine Of Patients With Ankylosing Spondylitis
Abstract Number: 190

A Meta-Analysis and Systematic Literature Review: Effect Of The Method Used To Measure Adherence In Rheumatoid Arthritis On Its Rate, and Evaluation Of Associated Factors
Abstract Number: 13

A MORE Specific Immunoassay For The Diagnosis Of APS
Abstract Number: 1312

A Multi-Biomarker Disease Activity Score Correlates With Radiographic Progression In Early Rheumatoid Arthritis: Results From a Randomized Trial
Abstract Number: 1347

A Multi-Biomarker Disease Activity Score For Rheumatoid Arthritis Predicts Radiographic Damage In The BeSt Study
Abstract Number: 413

A Multiple Cause-Of-Death Study In Rheumatoid Arthritis
Abstract Number: 971

A Needs Assessment and Review Curriculum Of Content Of Teaching On Systemic Lupus Erythematosus
Abstract Number: 1877

A Neutrophil Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes Is Associated With Organ-Specific Disease Activity In Systemic Lupus Erythematosus
Abstract Number: 2610

A New Pathogenic Role Of BAFF As a Critical Mediator Of Skin and Lung Fibrosis In Experimental Bleomycin-Induced Pulmonary Fibrosis, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis
Abstract Number: 2376

A Novel and Effective Prediction Model Of Response To Rituximab In Rheumatoid Arthritis
Abstract Number: 2746

A Novel Autoinflammatory Disorder Characterized By Ectodermal Dysplasia, Metaphyseal Chondrodysplasia, Growth Failure and Hyper-IgD In a Single Family

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].